JPMorgan Chase & Co. Cuts Organon & Co. (NYSE:OGN) Price Target to $12.00

Organon & Co. (NYSE:OGN) had its price target cut by JPMorgan Chase & Co. from $14.00 to $12.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an underweight rating on the stock.

Other analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Morgan Stanley decreased their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, Piper Sandler downgraded shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $12.50.

Organon & Co. Trading Down 1.3%

NYSE OGN opened at $7.61 on Tuesday. The company has a fifty day simple moving average of $9.25 and a two-hundred day simple moving average of $9.46. The stock has a market cap of $1.98 billion, a P/E ratio of 3.96, a P/E/G ratio of 1.63 and a beta of 0.59. Organon & Co. has a 12-month low of $6.18 and a 12-month high of $17.23. The company has a current ratio of 1.75, a quick ratio of 1.13 and a debt-to-equity ratio of 9.69.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the company earned $1.38 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. On average, analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th will be paid a $0.02 dividend. The ex-dividend date is Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. Organon & Co.’s dividend payout ratio is presently 4.17%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after purchasing an additional 3,650,860 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Organon & Co. by 8.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company’s stock worth $159,553,000 after buying an additional 820,378 shares in the last quarter. State Street Corp boosted its holdings in Organon & Co. by 6.0% during the second quarter. State Street Corp now owns 9,520,594 shares of the company’s stock worth $92,159,000 after buying an additional 540,478 shares in the last quarter. LSV Asset Management grew its position in Organon & Co. by 6.1% during the first quarter. LSV Asset Management now owns 7,980,775 shares of the company’s stock valued at $118,834,000 after buying an additional 455,699 shares during the period. Finally, Nordea Investment Management AB increased its holdings in Organon & Co. by 1.1% in the second quarter. Nordea Investment Management AB now owns 4,904,076 shares of the company’s stock valued at $48,281,000 after buying an additional 53,733 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.